Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine

Authors:

Abstract
The value of variant-adapted vaccines that are capable of inducing a higher and broader immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at booster vaccination is currently being evaluated.1-4 We conducted a multicenter, randomized, single-blind trial to assess the immunogenicity and safety of two adjuvanted recombinant vaccines and the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech) administered as a booster (ClinicalTrials.gov number, NCT05124171; EudraCT number, 2021-004550-33).
All Related Versions
Funding Information
  • Ministry of Health and Solidarity